ECSP034858A - Administración oral de hormona paratiroides y calcitonina - Google Patents

Administración oral de hormona paratiroides y calcitonina

Info

Publication number
ECSP034858A
ECSP034858A EC2003004858A ECSP034858A ECSP034858A EC SP034858 A ECSP034858 A EC SP034858A EC 2003004858 A EC2003004858 A EC 2003004858A EC SP034858 A ECSP034858 A EC SP034858A EC SP034858 A ECSP034858 A EC SP034858A
Authority
EC
Ecuador
Prior art keywords
oral administration
hormone
paratiroides
calcitonine
parathyroid hormone
Prior art date
Application number
EC2003004858A
Other languages
English (en)
Inventor
Joseph M Ault
Moise Azria
Simon David Bateman
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23136525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP034858(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP034858A publication Critical patent/ECSP034858A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un método para administrar oralmente una hormona paratiroides, PTH, el cual comprende co-administrar oralmente a un paciente que necesite hormona paratiroides, una cantidad efectiva de una hormona paratiroides, y una cantidad efectiva de una calcitonina. El método de acuerdo con la invención permite la administración oral de hormona paratiroides sin los efectos secundarios de hipercalcemia, hipercalcuria, y nefrolitiasis.
EC2003004858A 2001-06-01 2003-11-21 Administración oral de hormona paratiroides y calcitonina ECSP034858A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29516901P 2001-06-01 2001-06-01

Publications (1)

Publication Number Publication Date
ECSP034858A true ECSP034858A (es) 2004-01-28

Family

ID=23136525

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004858A ECSP034858A (es) 2001-06-01 2003-11-21 Administración oral de hormona paratiroides y calcitonina

Country Status (25)

Country Link
US (2) US20040186050A1 (es)
EP (1) EP1397156B1 (es)
JP (2) JP5073153B2 (es)
KR (3) KR20090116836A (es)
CN (2) CN101837120A (es)
AT (1) ATE356631T1 (es)
AU (2) AU2002344371B2 (es)
BR (1) BRPI0209748B1 (es)
CA (1) CA2446929C (es)
CO (1) CO5540323A2 (es)
CZ (1) CZ307145B6 (es)
DE (1) DE60218842T2 (es)
EC (1) ECSP034858A (es)
ES (1) ES2282436T3 (es)
HU (1) HU229613B1 (es)
IL (2) IL158777A0 (es)
MX (1) MXPA03011027A (es)
NO (1) NO330093B1 (es)
NZ (1) NZ529439A (es)
PL (1) PL211976B1 (es)
PT (1) PT1397156E (es)
RU (1) RU2300392C2 (es)
SK (1) SK287697B6 (es)
WO (1) WO2002098453A2 (es)
ZA (1) ZA200308625B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5073153B2 (ja) 2001-06-01 2012-11-14 ノバルティス アーゲー 副甲状腺ホルモンおよびカルシトニンの経口投与
DE60233803D1 (de) 2001-08-17 2009-11-05 Novartis Ag 5-cnac zur oralen verabreichung von parathormonfragmenten
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
PE20070548A1 (es) 2005-09-19 2007-07-12 Emisphere Tech Inc Formas cristalinas de la sal de di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
WO2007059470A2 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
AU2006318815B2 (en) * 2005-11-17 2010-08-19 Novartis Ag Pharmaceutical composition
US8022048B2 (en) 2007-11-02 2011-09-20 Emisphere Technologies, Inc. Method of treating vitamin B12 deficiency
CN104857505A (zh) * 2008-08-18 2015-08-26 安特拉贝欧有限公司 用于口服给予蛋白质的方法和组合物
CN102123697B (zh) * 2008-08-18 2015-06-10 安特拉贝欧有限公司 用于口服给予蛋白质的方法和组合物
WO2011071480A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2012130193A1 (en) 2011-03-31 2012-10-04 Zentiva, K.S. Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
CN104800564A (zh) * 2015-04-02 2015-07-29 中国人民解放军济南军区总医院 一种治疗血虚不荣型甲状旁腺功能减退症的中药组合物
KR101796604B1 (ko) * 2016-08-30 2017-11-10 목포대학교 산학협력단 위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형
WO2019098811A2 (ko) 2017-11-20 2019-05-23 주식회사 노브메타파마 Chp(시클로-히스프로)를 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물
KR102115353B1 (ko) * 2019-05-17 2020-05-26 주식회사 노브메타파마 Chp(사이클로-히스프로) 및 부갑상선 호르몬을 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
US5364840A (en) * 1989-12-05 1994-11-15 Vical, Inc. Synthetic calcitonin peptides
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
JPH08507070A (ja) * 1993-02-22 1996-07-30 アルザ・コーポレーション 活性物質の経口投与のための組成物
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US5955574A (en) * 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
ATE383169T1 (de) 1997-02-07 2008-01-15 Emisphere Tech Inc Komponente und zusammensetzungen zur verabreichung von wirkstoffen
AR012448A1 (es) * 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
DE19915272A1 (de) * 1999-04-03 2000-10-05 Vetter & Co Apotheker Spritze für medizinische Zwecke
NZ534409A (en) * 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
WO2001032201A2 (en) 1999-10-29 2001-05-10 Eli Lilly And Company A pharmaceutical composition having high cell membrane permeability
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
JP5073153B2 (ja) 2001-06-01 2012-11-14 ノバルティス アーゲー 副甲状腺ホルモンおよびカルシトニンの経口投与
DE60233803D1 (de) * 2001-08-17 2009-11-05 Novartis Ag 5-cnac zur oralen verabreichung von parathormonfragmenten
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone

Also Published As

Publication number Publication date
CZ307145B6 (cs) 2018-02-07
BRPI0209748B1 (pt) 2015-11-24
EP1397156B1 (en) 2007-03-14
KR101320817B1 (ko) 2013-10-21
IL158777A0 (en) 2004-05-12
US20080119411A1 (en) 2008-05-22
IL158777A (en) 2012-06-28
RU2003136733A (ru) 2005-05-20
JP5073153B2 (ja) 2012-11-14
DE60218842T2 (de) 2007-12-20
KR20090116836A (ko) 2009-11-11
JP2010189423A (ja) 2010-09-02
PL211976B1 (pl) 2012-07-31
HUP0400120A2 (hu) 2005-04-28
CA2446929A1 (en) 2002-12-12
NZ529439A (en) 2005-11-25
WO2002098453A2 (en) 2002-12-12
NO330093B1 (no) 2011-02-14
EP1397156A2 (en) 2004-03-17
AU2002344371B2 (en) 2006-06-29
CO5540323A2 (es) 2005-07-29
AU2006225157B2 (en) 2009-04-23
ZA200308625B (en) 2004-07-13
DE60218842D1 (de) 2007-04-26
BR0209748A (pt) 2004-07-27
NO20035133D0 (no) 2003-11-18
US20040186050A1 (en) 2004-09-23
KR20040007617A (ko) 2004-01-24
US8153587B2 (en) 2012-04-10
CN101837120A (zh) 2010-09-22
WO2002098453A3 (en) 2003-07-31
AU2006225157A1 (en) 2006-10-19
NO20035133L (no) 2003-11-18
ES2282436T3 (es) 2007-10-16
SK287697B6 (sk) 2011-06-06
KR20120065429A (ko) 2012-06-20
RU2300392C2 (ru) 2007-06-10
SK14752003A3 (sk) 2004-06-08
ATE356631T1 (de) 2007-04-15
CA2446929C (en) 2013-04-09
JP2005500277A (ja) 2005-01-06
CZ20033232A3 (cs) 2004-06-16
HU229613B1 (en) 2014-03-28
PT1397156E (pt) 2007-05-31
PL364089A1 (en) 2004-12-13
HUP0400120A3 (en) 2012-09-28
MXPA03011027A (es) 2004-03-19
CN1512892A (zh) 2004-07-14

Similar Documents

Publication Publication Date Title
NO20035133D0 (no) Oral administrering av paratyroidhormon og kalsitonin
AR033639A1 (es) Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
GT199800177A (es) Combinacion eficaz para el tratamiento de la impotencia .
AR037109A1 (es) Uso de flibanserina
UY27296A1 (es) Composición farmacéutica que contiene mosaprida y pancreatina
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
PE58998A1 (es) Terapia combinada para la osteoporosis
DE69831869D1 (de) Verbesserte verabreichungstechnik für multiple medikamentengaben
BR0005938A (pt) Composição de dosagem oral com libaraçãoprolongada
DE69934831D1 (de) MULTIPLEXES, FüR DIE ORALE VERBABREICHUNG GEEIGNETES MEDIKAMENTENABGABESYSTEM
CY1109661T1 (el) 5-cnac ως παραγοντας για χορηγηση απο το στομα τμηματων παραθορμονης
AU3787601A (en) New self emulsifying drug delivery system
AR013479A1 (es) Metodo para aumentar el volumen oseo utilizando agonistas de prostanoide f selectivos no naturales.
UY27505A1 (es) Tableta masticable que contiene lisina
MA26808A1 (fr) Analogues de la vitamine d3.
AR046402A1 (es) Combinacion de principio activo que comprende un compuesto 2,5-dihidrobencenosulfonico y un modulador de los canales de potasio
CY1108413T1 (el) Ενεσιμη φαρμακευτικη συνθεση που περιλαμβανει αιθανολη για την αγωγη των δισκοπαθειων
AR040737A1 (es) Administracion oral de calcitonina
ES2154348T3 (es) Analogos de prostaglandina administrados por via oral o vaginal para el tratamiento sistematico de la tercera etapa del parto.
ES2179302T3 (es) Formas galenicas y sus utilizaciones.
CL2004000767A1 (es) Unidad de dosificacion oral que comprende un agente antagonista de bombas de protones y excipientes de caracter basico; procedimiento para su preparacion, utiles para tratar enfermedades causadas por una secrecion aumentada de acidos gastricos.
ITRM20030074A0 (it) Formulazioni semisolide a rilascio immediato intese per la somministrazione orale di farmaci.
PE20030732A1 (es) Empleo de alquilfosfocolinas en el tratamiento preventivo de enfermedades causadas por protozoarios
AR018321A1 (es) Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
AR106246A2 (es) Formulación farmacéutica de cladribina para tratamiento de esclerosis múltiple y uso